This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Herbals LLC has issued a nationwide recall of all lots of Vail-Bon Jie Yang Wan  supplement capsules due to the presence of ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK 's new drug application (NDA) for Blenrep ...

The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug applica ...